DeepMed Research

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Phase 3

Completed

Conditions: Metastatic Breast Cancer
Locally Advanced Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Exemestane

First Posted Date: 2003-07-23

Last Posted Date: 2015-02-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 694

Registration Number: NCT00065325

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom

Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.

Phase 2

Terminated

Conditions: Colorectal Neoplasms
Metastases, Neoplasm

First Posted Date: 2003-07-18

Last Posted Date: 2011-01-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 180

Registration Number: NCT00065117

Locations: 🇺🇸
Research Site, Pittsburgh, Pennsylvania, United States

Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: AC2993 (exenatide)
Drug: daclizumab (immunosuppressive)

First Posted Date: 2003-07-11

Last Posted Date: 2015-03-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 47

Registration Number: NCT00064714

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease
COPD

First Posted Date: 2003-06-10

Last Posted Date: 2016-11-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 1000

Registration Number: NCT00062582

Locations: 🇺🇸
ATLANA Pharma, Cities in Colorado, Colorado, United States
🇵🇪
ALTANA Pharma, Cities in Peru, Peru

Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

Phase 3

Completed

Conditions: Cerebral Stroke
Stroke, Acute
Cerebrovascular Stroke
Ischemic Attack, Transient

First Posted Date: 2003-05-21

Last Posted Date: 2010-11-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 3200

Registration Number: NCT00061022

Locations: 🇬🇧
Research Site, Newcastle-upon-Tyne, United Kingdom

Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

Phase 3

Completed

Conditions: Bipolar Disorder
Depression, Bipolar

First Posted Date: 2003-05-08

Last Posted Date: 2011-01-26

Lead Sponsor: AstraZeneca

Registration Number: NCT00060489

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms
Metastases, Neoplasm

Interventions: Drug: ZD4054 10 mg
Drug: ZD4054 15 mg
Drug: ZD4054 22.5 mg

First Posted Date: 2003-03-04

Last Posted Date: 2012-10-31

Lead Sponsor: AstraZeneca

Target Recruit Count: 22

Registration Number: NCT00055471

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

Arimidex in McCune Albright Syndrome

Phase 2

Completed

Conditions: McCune-Albright Syndrome

Interventions: Drug: Arimidex 1 mg

First Posted Date: 2003-02-26

Last Posted Date: 2015-09-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 40

Registration Number: NCT00055302

Locations: 🇬🇧
Research Site, London, United Kingdom

Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: AC2993

First Posted Date: 2002-09-05

Last Posted Date: 2015-02-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 155

Registration Number: NCT00044668

Locations: 🇭🇺
Uzsoki Street Municipal Hospital, Budapest, Hungary
🇭🇺
Peterfy Teaching Hospital, Budapest, Hungary
🇭🇺
Diagnostic Units Hungary Kft., Budapest, Hungary

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Non-Insulin-Dependent

Interventions: Drug: AC2993 7.5 mcg
Drug: Placebo 0.03 mL
Drug: Placebo 0.01 mL
Drug: Placebo 0.04 mL
Drug: AC2993 2.5 mcg
Drug: Placebo 0.02 mL
Drug: AC2993 10.0 mcg
Drug: AC2993 5.0 mcg

First Posted Date: 2002-09-05

Last Posted Date: 2015-02-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 156

Registration Number: NCT00044694

Locations: 🇺🇸
Carolina Advanced Research, Cary, North Carolina, United States
🇺🇸
Fallen Timbers Internal Medicine, LLC, Maumee, Ohio, United States
🇺🇸
Utah Diabetes Center at the University of Utah, Salt Lake City, Utah, United States

and more 29 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy